Introduction. The objectives of this survey were to assess the seroprevalence of antibodies to poliovirus types 1 and 3 and the impact of bivalent (types 1 and 3) oral poliovirus vaccine (bOPV) use in immunization campaigns in northern India.
INTRODUCTION
With the last case of poliomyelitis reported in January 2011, India has been free of polio for nearly 3 years. Before this success, wild poliovirus (WPV) circulation in India had persisted in certain areas of the polioendemic states of Uttar Pradesh and Bihar for several years. To interrupt transmission of WPV in these last reservoirs, multiple doses of monovalent (type 1) oral poliovirus vaccine (mOPV1) were provided in almost monthly campaigns during [2005] [2006] [2007] [2008] [2009] . Monovalent OPV type 3 (mOPV3) and trivalent OPV (tOPV) were provided occasionally in campaigns, and tOPV was provided through routine immunization (RI) services. This strategy successfully reduced paralytic cases due to type 1 WPV but was associated with outbreaks of type 3 WPV infection during 2007-2009 in both Uttar Pradesh and Bihar [1] [2] [3] [4] .
In a clinical trial conducted during 2009 in central and southern India, administration of 2 doses of bivalent (types 1 and 3) OPV (bOPV) to infants at birth and 4 weeks of age resulted in seroconversion of 86% to type 1 and 74% to type 3 poliovirus. Because seroconversion after administration of 2 bOPV doses was not inferior to seroconversion after 2 doses of the respective monovalent vaccines [5] , the Global Advisory Committee on Polio Eradication recommended the administration of bOPV in immunization rounds, also called supplementary immunization activities (SIAs), in areas with simultaneous circulation of both type 1 and type 3 wild poliovirus [6] . The India Expert Advisory Group recommended the use of bOPV in areas of Uttar Pradesh and Bihar at high risk of WPV transmission.
Given the history of lower efficacy of oral poliovirus vaccines in Uttar Pradesh compared with the rest of the subcontinent [3, 7] , it was important to assess the impact of bOPV introduction in northern India to direct future eradication efforts [8] . This report presents the results of a cross-sectional seroprevalence study conducted in August 2010 in Uttar Pradesh and Bihar. The objectives of this study were (1) to estimate the prevalence of seropositivity to type 1, type 2, and type 3 poliovirus in populations at high risk of WPV transmission; (2) to assess the impact of introducing bOPV in SIAs on the immunity to type 1 and 3 poliovirus; and (3) to identify risk factors associated with low seroprevalence to poliovirus in this population.
METHODS

Sample Selection
Because the objective of the study was to estimate seroprevalence in populations at the highest risk for paralysis, we conducted the survey among young infants residing in 20 blocks (rural subdistricts) in Uttar Pradesh and Bihar with the highest case incidence and/or duration of type 1 WPV transmission in the preceding 5 years. We selected infants 6-7 months of age because they are expected to have the lowest seroprevalence (with passive immunity having mostly waned and active immunity having not been fully established). In addition, because >10 OPV doses per year were administered through campaigns in districts of Uttar Pradesh and Bihar with a high risk of WPV transmission, focusing on individuals aged 6-7 months provided the best opportunity to estimate the per-dose immunogenicity of bOPV in subgroups that had received fewer doses of each vaccine formulation.
The survey design was a community-based stratified cluster sample. Within each of the 20 blocks, 10 vaccination-team areas and 2 replacement areas were selected by simple random sampling. Each vaccination-team area in polio SIAs has about 300-600 houses, and microplans are updated before each campaign. Target enrollment was 6 children from each vaccinationteam area. Replacement areas were included when insufficient numbers of eligible children were found.
A sample of 600 children per state (6 children per area × 10 areas per block × 10 blocks) would provide a margin of error of 2.5% for a seroprevalence of 95% (type 1) and 5.2% for a seroprevalence of 70% (type 3), assuming a 0.95 probability of obtaining an estimate within the desired margin of error and design effect of 2.
Enrollment and Study Procedures
Selection of children was done in 2 phases. During the first phase (screening), field staff went house to house, starting from a randomly selected first house and following the same route as the vaccination teams follow during SIAs until 10-12 households with eligible children were identified or the entire vaccinationteam area was canvassed. Eligibility was defined as birth date from 16 December to 17 February 2010 (corresponding to an approximate age of 6-7 months) and residence in the area for >1 month.
A few days after households with eligible children were identified, a medical officer visited the households, performed a medical examination, and explained the survey to the parents. No follow-up attempts were made if the parent or child was not at home. Infants were selected to participate in the survey if the medical officer confirmed (1) birth within the correct dates; (2) residence in the area for >1 month; (3) absence of contraindications for venipuncture, major illness, or acute illness requiring hospitalization; and (4) agreement by the parents to participate. For subjects who fulfilled these conditions, the medical officers inquired about their history of diarrhea, defined as ≥3 loose stools per day or 1 loose stool with blood during the previous 14 days, and obtained a standardized vaccination history. The history of doses received through RI services was abstracted from vaccination cards, when available, or determined through parental recall. When parents reported >4 RI tOPV doses, the child was assumed to have received 4 doses, since the infant immunization schedule only includes 4 doses at 0, 6, 10, and 14 weeks of age. The history of SIA-associated doses in Bihar was abstracted from vaccination cards, when available, or determined through parental recall. In Uttar Pradesh, the history of SIA-associated doses was abstracted from newborn booklets maintained by local community mobilization coordinators, when available, or determined through parental recall. To attain the most accurate parent-reported estimates of doses received during SIAs, the medical officer used a schedule of local holidays and festivals and campaigns conducted in the district and also checked parents' answers with vaccination records compiled during SIAs.
After the interview, infants and parents were escorted to a study health facility for anthropometric measurements and blood collection. Informed consent was obtained from parents or guardians. The presence of stunting (ie, low length for age) and wasting (ie, low weight for length) was evaluated using reference tables from a standard international population [9] . Values for length for age or weight for length that were ≥2 SDs below the standard mean were considered moderate stunting or wasting. Values that were ≥3 SD below the mean were considered severe stunting or wasting. One milliliter of blood was collected by venipuncture for poliovirus antibody determination, and an additional drop was used for rapid hemoglobin determination with the Hemocue method; the test was also offered to mothers [10] . All infants and mothers received prophylactic iron and folic acid supplements as per the national guidelines [11] , and they were referred for follow up at the primary health center if anemia was detected. Informed consent was obtained from parents or guardians. The study was approved by the ethics review boards of the Indian Council of Medical Research and the World Health Organization.
Determination of Poliovirus Antibodies
Blood samples were centrifuged within 3 hours of collection, and serum samples were stored at 2°C-8°C for 2-3 days and then frozen at −20°C before shipment to the Enterovirus Research Center for testing. Neutralizing antibody titers against poliovirus types 1, 2, and 3 were determined in triplicate, using a modified microneutralization assay previously described [12, 13] . Unobserved titers (ie, those below the starting and above the ending dilution) were assigned values of <8 and ≥1448, respectively. On the assumption that maternal antibody titers decline to undetectable levels by age 6 months, seropositivity was defined as a reciprocal titer of ≥8.
Statistical Analysis
Information from questionnaires was double entered and validated for errors with MS Access 2003 (Microsoft). Analyses
were conducted with SAS, version 9.2 (SAS Institute, Cary, NC), and SUDAAN, version 10 (RTI International, Research Triangle Park, NC) [14, 15] .
Seroprevalence and 95% confidence limits were estimated for each serotype, stratified by demographic and clinical factors. The Wald F test was used to assess factors associated with being seropositive for each serotype and for comparisons between Bihar and Uttar Pradesh. Adjusted prevalence ratios and 95% confidence intervals (CIs) were calculated from multivariable logistic models in SUDAAN [16] . The models were first fit including 2-way interactions and fit again omitting nonsignificant variables and interactions (P ≥ .05). Variance estimates were calculated using the Taylor linearization method, accounting for the stratified-cluster design and sampling weights.
RESULTS
Study Population
The fieldwork was conducted during 12-22 August 2010. During the enrollment phase, interviewers visited 2519 houses with eligible children; parents refused participation in 86 (3%) households visited, 38 (2%) infants were excluded due to contraindications for participation, and eligibility could not be confirmed for 198 (8%) infants. A total of 1299 infants were enrolled ( Figure 1) ; after exclusion of 19 participants due to Demographic and clinical parameters of the study participants are shown in Table 1 . Males accounted for approximately half of the participants in both states. The proportion of illiterate parents was higher in Bihar than in Uttar Pradesh; the proportions of women with anemia and infants with malnutrition or recent diarrhea were higher in Uttar Pradesh.
Doses of OPV Received Through RI Services and SIAs
Vaccination cards with information on tOPV administered during RI were available for 522 (80%) infants from Bihar and 328 (53%) infants from Uttar Pradesh. A strong correlation was observed between the number of doses determined through parental recall and the number recorded on vaccination cards among 840 infants with information from both sources (Spearman correlation, 0.80). The proportion of infants who had received at least 3 RI tOPV doses was 67% (95% CI, 61%-72%) in Bihar and 27% (95% CI, 23%-32%) in Uttar Pradesh. The median number of RI tOPV doses received was 3 (interquartile range [IQR], 2-3) in Bihar, compared with 1 (IQR, 0-3) in Uttar Pradesh.
During the life of the study participants, 7-8 SIAs were conducted, with different vaccine formulations distributed in different districts in some SIAs. Only infants 7 months old received vaccine during the January round, which distributed tOPV in Uttar Pradesh and bOPV in Bihar. During SIA rounds conducted from February to June 2010, >95% of study subjects received a vaccine dose, which included bOPV (3 rounds) and mOPV1 (2 rounds) in both Uttar Pradesh and Bihar. The July round was geographically restricted and provided mOPV3 to infant residents in 1 block of Uttar Pradesh and 1 block of Bihar. Overall, during SIA rounds, 1161 study participants (91%) in both states received 2 mOPV1 doses, and 1062 (83%) received ≥3 bOPV doses; 272 infants (44%) in Uttar Pradesh received 1 tOPV dose, and 36 (5%) in Uttar Pradesh and 63 (10%) in Bihar received 1 mOPV3 dose ( Table 2 ). The median number of doses received during SIAs for all infants was 3 
Seroprevalence, Univariate Analysis
Among all study participants, seroprevalences for types 1, 2, and 3 poliovirus were 98% (95% CI, 97%-99%), 66% (95% CI, 62%-69%), and 77% (95% CI, 75%-79%), respectively, with no significant differences between infants enrolled in Uttar Pradesh and Bihar (Table 3) . Results from Uttar Pradesh and Bihar were combined to analyze the seroprevalence to each poliovirus type by epidemiological and clinical characteristics. Overall, 97% (95% CI, 94%-99%) of infants were seropositive to type 1 after ≥3 doses of bOPV and/or mOPV1; calculation of seroprevalence was not possible for infants who received 0-1 dose, because of small sample sizes (Figure 2A ). Seroprevalence for type 2 was 24% (95% CI, 17%-32%) among infants who had received 0 tOPV doses, 64% (95% CI, 56%-71%) after 1 dose, 65% (95% CI, 58%-71%) after 2 doses, 76% (95% CI, 71%-80%) after 3 doses, and 86% (95% CI, 81%-91%) after 4 doses ( Figure 2D ). When 272 infants from Uttar Pradesh who had received tOPV in an SIA were excluded, overall seroprevalence was 64% (95% CI, 60%-69%) in Bihar and 50% (95% CI, 44%-56%) in Uttar Pradesh (P < .01).
Seroprevalence for type 3 among infants who had received 0 tOPV doses was 50% (95% CI, 27%-73%) after receiving 2 bOPV doses, 77% (95% CI, 69%-83%) after 3 bOPV doses, and 83% (95% CI, 64%-93%) after 4 bOPV doses ( Figure 2E ). Among infants who had received any tOPV doses, seroprevalence was 75% (95% CI, 67%-78%) after 3 doses of type 3-containing vaccine and increased up to 89% (95% CI, 82%-93%) for those who received 8-9 doses ( Figure 2F ).
Fewer years of parents' education was associated with lower seroprevalences to types 2 and 3 ( Table 4 ). The proportion of infants seropositive to type 3 was 79% (95% CI, 76%-82%) among those without wasting (ie, low weight for height), compared with 67% (95% CI, 59%-74%) among those with severe wasting (P < .05).
Logistic Regression Analysis
Logistic regression analysis could only be conducted for types 2 and 3 because 98% of study subjects were seropositive to type 1. The final logistic regression model for seroprevalence to type The source of information for the number of RI tOPV doses received were immunization cards in 850 study subjects and parent recall in 428 subjects. Infants whose parents reported having received >4 RI tOPV doses were included in the group of 4 doses. For 2 infants data about RI-associated doses received are missing, and for 6 infants, data about SIA-associated doses received are missing.
Abbreviations: bOPV, bivalent oral poliovirus vaccine; mOPV1, monovalent oral poliovirus type 1 vaccine; mOPV3, monovalent oral poliovirus type 3 vaccine; tOPV, trivalent oral poliovirus vaccine; UP, Uttar Pradesh. 2 included a continuous variable for the number of RI-associated tOPV doses received, SIA-associated tOPV receipt, father's education level, and state of residence. The interaction between state and the number of RI-associated tOPV doses was not statistically significant (P = .6) and was omitted. The prevalence ratio for type 2 was 1.34 (95% CI, 1.24-1.44) for each additional RI-associated tOPV dose. Infants from Uttar Pradesh who received 1 SIA-associated tOPV dose were 1.53 (95% CI, 1.41-1.66) times as likely to be seropositive, compared with those who did not receive an SIA-associated dose, after control for the number of RI-associated tOPV doses received and father's education level (Table 5) .
On the basis of a prior study showing similar immunogenicity for mOPV3 and bOPV and higher immunogenicity for Figure 2 . Seroprevalence and median reciprocal titers for poliovirus types 1, 2, and 3, by number of oral poliovirus vaccine (OPV) doses received. For each poliovirus type, the number of OPV doses received are shown on the x-axis; the proportion of infants seropositive for each type of poliovirus, with their 95% confidence intervals (CIs), are represented on the left y-axis; and the median reciprocal antibody titers are represented on the right y-axis. Numbers above the x-axis are the number of study subjects tested for each seroprevalence estimate. Abbreviations: bOPV, bivalent oral poliovirus vaccine; mOPV1, monovalent oral poliovirus type 1 vaccine; mOPV3, monovalent oral poliovirus type 3 vaccine; RI, routine immunization; SIA, supplementary immunization activity; tOPV, trivalent oral poliovirus vaccine.
bOPV or mOPV3, compared with tOPV [5] , the model for type 3 seroprevalence included separate variables for the number of RI-associated tOPV doses received and the number of mOPV3 or bOPV doses received. Receipt of an SIA-associated tOPV dose and presence of wasting or stunting were also included. The prevalence ratio for type 3 seropositivity was 1.05 (95% CI, 1.01-1.08) for each additional RI-associated tOPV dose and 1.15 (95% CI, 1.03-1.29) for each additional mOPV3 or bOPV dose. Infants who received 1 SIA-associated tOPV dose had a 1.11 (95% CI, 1.03-1.20) higher probability of being seropositive, compared with those who did not receive an SIAassociated dose (Table 5) . After adjustment for OPV doses received, severe wasting ( prevalence ratio, 0.85; 95% CI, .75-.97) and moderate or severe stunting (odds ratio, 0.93; 95% CI, .87-1.00) were associated with lower type 3 seroprevalence.
DISCUSSION
This seroprevalence study confirmed that very high levels of population immunity to type 1 poliovirus were maintained and that the immunity gap to type 3 poliovirus narrowed after mOPV1 was replaced with bOPV in SIAs conducted in northern India beginning in January 2010. In a study conducted in May 2009 in Moradabad, Western Uttar Pradesh, type 1 seroprevalence was 99% and type 3 seroprevalence was 49% among 534 infants 6-7 months of age who had received a median of 6 SIA-associated mOPV1 doses and 2 RI-associated tOPV doses [17] . In this study, type 1 seroprevalence was 98% and type 3 seroprevalence was 77% among infants 6-7 months of age who had received a median of 3 bOPV doses, 2 mOPV1 doses, and 3 tOPV doses. These results provide a biological explanation for the reduction in cases of paralytic polio due to WPV type 3 without a reemergence of WPV type 1 circulation observed in northern India after bOPV introduction [18] . The seroprevalence results from our study and from the 2009 Moradabad study and the absence of WPV type 3 transmission in India during 2010 and 2011 suggest that the level of population immunity required to stop circulation of WPV type 3 in areas of endemicity is lower than the level required to stop WPV type 1 circulation. This finding might be related to lower transmissibility of WPV type 3, compared with WPV type 1 [19] . In this study, it was not possible to independently evaluate the per-dose immunogenicity of polio vaccines against type 1 poliovirus because most study participants had already received several doses of mOPV1 and bOPV. However, since the type 1 seroprevalence was almost 90% after 3 doses and >98% after ≥4 doses and because high antibody titers were achieved, our findings suggest that the immunogenicities of bOPV and mOPV1 are within the range observed in clinical trials in other parts of India, where the type 1 seroconversion was 86% (95% CI, 79%-90%) after 2 bOPV doses and 87% (80%-92%) after 2 mOPV1 doses [5] . These results, together with the observations of the 2009 Moradabad study [17] , suggest that population immunity levels of >95% can be achieved in northern India with <8 mOPV1 (and possibly bOPV) doses as previously estimated from case-control analysis [7] .
In this study, type 3 seroprevalence among infants who had received 0 tOPV doses was approximately 50%, 77%, and 82% after 2, 3, and 4 doses of bOPV, respectively, compared with 74% (95% CI, 66%-80%) after 2 bOPV doses in a study conducted in other parts of India [5] . The high prevalence of malnutrition (approximately 34% of infants with wasting or stunting) is a possible explanation for lower type 3 immunogenicity in this study, since malnutrition was associated with a lower type 3 immune response. Whether the effect of malnutrition on the immune response to type 3 polio vaccine is due to protein-calorie deficiency, the deficiency of specific nutrients, or to repeated acute episodes of diarrhea manifested by malnutrition [3, 7, [20] [21] [22] [23] [24] [25] [26] warrants further investigation. Type 2 seroprevalence was similar in Uttar Pradesh (67%) and Bihar (65%) despite higher 3-dose RI-associated tOPV coverage in Bihar (67%) than in Uttar Pradesh (27%). In our logistic regression model, which controlled for the number of RI-associated doses received in both states, higher type 2 seropositivity among infants in Uttar Pradesh was associated with administration of an extra SIA-associated tOPV, which suggests that tOPV delivered through SIAs had higher immunogenicity than tOPV delivered through RI. These results agree with prior observations in other countries and can be explained by intense secondary spread of vaccine virus from vaccinees to close contacts during campaigns and by temporary displacement by vaccine poliovirus of other enteric pathogens, particularly enterovirus, that can interfere with the development of an immune response to OPV [27] [28] [29] [30] . Improved maintenance of cold chain during SIAs, compared with RI services, might be of less importance since the late 1990s, when vaccine vial monitors were included on OPV vials, allowing vaccinators to identify and discard vaccine vials exposed to high temperatures long enough to have lost potency [31] .
The participation rate for families at home was >90%. Because of logistical constraints, we did not return to households where no one was home, and we have insufficient information to determine whether this biased our estimates. The sources of vaccination history ( parental recall or immunization cards) could not be validated with clinic records. Finally, immunity to poliovirus may have been acquired through contact with vaccinees or infection with WPV, although WPV infection is unlikely because of the low number of WPV cases reported in Uttar Pradesh and Bihar during the lifetime of the study participants.
Although this study provides estimates of population immunity only for the high-risk blocks studied, the results have important implications for future vaccination strategies in India and other countries at risk of WPV circulation. First, our findings indicate that bOPV is very effective in areas with circulation of polioviruses types 1 and 3. Replacement of mOPV1 with bOPV in SIAs can reduce the total number of doses required to achieve and maintain high immunity levels against type 1 without losing immunity to type 3. Second, multiple doses of type 3-containing vaccines were needed to close immunity gaps to type 3 in underserved areas with a high prevalence of malnutrition, which might require distribution of multiple bOPV or mOPV3 doses in SIAs, in addition to reaching high RI coverage. Finally, strengthening RI coverage in Uttar Pradesh and Bihar is important to maintain population immunity to all polioviruses and keep India polio free [32] .
Notes
